Cytochrome P–450 gene and drug interaction analysis in patients referred for pharmacogenetic testing
- 15 January 2016
- journal article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 73 (2) , 61-67
Abstract
Purpose The results of a study of variant cytochrome P-450 (CYP) alleles and associated risks of drug–drug interactions (DDIs) and altered drug metabolism are reported. Methods The records of a pharmacogenetic testing laboratory were retrospectively analyzed to identify patients tested for polymorphisms of genes coding for five CYP isozymes important in drug metabolism (CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5) over a 16-month period. Based on the results of phenotyping, the patients were categorized by expected CYP isozyme activity (e.g., normal or poor metabolizer, expresser or nonexpresser). Using proprietary Web-based software, researchers analyzed phenotyping data and medication lists submitted by patients to determine the potential for DDIs, drug–gene interactions (DGIs), and drug–drug–gene interactions (DDGIs). Results In the mixed-race study population of more than 22,000 male and female patients (age range, 1–108 years; mean, 60 years), phenotypes associated with alterations of CYP metabolic pathways were common. Among patients in whom phenotypes for all five isozymes of interest were determined (n = 14,578), about 93% were not categorized as normal metabolizers of all five proteins. In many cases, potential interaction threats were rated by clinicians as severe enough to warrant implementation or consideration of a medication regimen change or dose adjustment. Analysis of patient-provided medication lists indicated frequent use of medications posing DDI, DGI, or DDGI risks. Conclusion In a mixed-race population of over 20,000 U.S. patients, CYP gene polymorphisms associated with DDIs and other interaction threats were prevalent, and most individuals were not categorized as normal metabolizers of all five CYP isozymes of interest.Keywords
This publication has 8 references indexed in Scilit:
- A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel usersGenetics in Medicine, 2015
- How Common are Drug and Gene Interactions? Prevalence in a Sample of 1143 Patients with CYP2C9 , CYP2C19 and CYP2D6 GenotypingPharmacogenomics, 2014
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variationPharmacology & Therapeutics, 2013
- Chapter 7: PharmacogenomicsPLOS Computational Biology, 2012
- Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and futureTrends in Pharmacological Sciences, 2004
- PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19Drug Metabolism and Disposition, 2003
- Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic ActivityDrug Metabolism and Disposition, 2000